enGene Therapeutics Inc. (ENGN): Total Assets
$221.47M
As of 2025-10-31
$288.32M
As of 2026-07-31
+110.0%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | $221.47M | -28.8% | 2025-12-22, Balance as of period end |
| 2024-10-31 | $311.17M | +257.8% | 2025-12-22, Balance as of period end |
| 2023-10-31 | $86.96M | +263.7% | 2024-12-19, Balance as of period end |
| 2022-10-31 | $23.91M | n/a | 2024-01-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $221.47M | -28.8% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $221.10M | -31.9% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $219.59M | +56.4% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $223.70M | -36.7% |
| Agenus Inc (AGEN) | 2025-12-31 | $226.80M | +0.2% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $228.79M | -38.4% |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $232.54M | +23.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $233.72M | +256.0% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $209.47M | +15.4% |
Compare ENGN, MGX, CMPX, IPSC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗